Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results